MX2020002241A - Anticuerpos anti-tm4sf y métodos de uso de los mismos. - Google Patents

Anticuerpos anti-tm4sf y métodos de uso de los mismos.

Info

Publication number
MX2020002241A
MX2020002241A MX2020002241A MX2020002241A MX2020002241A MX 2020002241 A MX2020002241 A MX 2020002241A MX 2020002241 A MX2020002241 A MX 2020002241A MX 2020002241 A MX2020002241 A MX 2020002241A MX 2020002241 A MX2020002241 A MX 2020002241A
Authority
MX
Mexico
Prior art keywords
methods
same
antibodies
tm4sf1
tm4sf1 antibodies
Prior art date
Application number
MX2020002241A
Other languages
English (en)
Inventor
Harold F Dvorak
Leonard G Presta
Paul A Jaminet
Shou-Ching S Jaminet
Original Assignee
Angiex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiex Inc filed Critical Angiex Inc
Publication of MX2020002241A publication Critical patent/MX2020002241A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se describen anticuerpos anti-TM4SF1, y sus fragmentos de unión al antígeno, que se unen a un epítopo en el bucle ECL2 de TM4SF1 humano. También se describen métodos de uso de dichos anticuerpos y fragmentos, incluso para la inhibición de la metástasis.
MX2020002241A 2017-08-28 2018-08-28 Anticuerpos anti-tm4sf y métodos de uso de los mismos. MX2020002241A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762550994P 2017-08-28 2017-08-28
PCT/US2018/048402 WO2019046338A1 (en) 2017-08-28 2018-08-28 ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
MX2020002241A true MX2020002241A (es) 2020-09-03

Family

ID=65526015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002241A MX2020002241A (es) 2017-08-28 2018-08-28 Anticuerpos anti-tm4sf y métodos de uso de los mismos.

Country Status (8)

Country Link
US (3) US11208495B2 (es)
EP (1) EP3675906A4 (es)
JP (2) JP7241080B2 (es)
CN (1) CN111565750B (es)
AU (1) AU2018323470A1 (es)
CA (1) CA3074111A1 (es)
MX (1) MX2020002241A (es)
WO (1) WO2019046338A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018323470A1 (en) * 2017-08-28 2020-03-19 Angiex, Inc. Anti-TM4SF1 antibodies and methods of using same
AU2019284915A1 (en) * 2018-06-12 2021-01-14 Angiex, Inc. Antibody-oligonucleotide conjugates
CN110734494B (zh) * 2019-10-30 2021-04-30 上海市第一人民医院 抗tspan8单克隆抗体及其用途
WO2021222783A1 (en) * 2020-05-01 2021-11-04 Angiex, Inc. Anti-tm4sf1 antibody drug conjugates and methods of using same
WO2022026915A2 (en) * 2020-07-31 2022-02-03 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
AU2022242927A1 (en) * 2021-03-26 2023-10-05 Angiex, Inc. Combinations comprising anti-tm4sf1 antibodies and immunotherapeutic agents and methods of using the same
CA3213065A1 (en) * 2021-03-26 2022-09-29 Paul A. JAMINET Maytansine-antibody conjugates and methods of using same
JPWO2022255401A1 (es) * 2021-06-03 2022-12-08
WO2022255843A1 (ko) * 2021-06-03 2022-12-08 주식회사 메드팩토 Tm4sf19 억제제 및 이의 용도

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US20040214872A1 (en) 2002-09-26 2004-10-28 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
CN101952454B (zh) 2008-02-08 2014-06-04 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
EP2385114A4 (en) * 2008-12-25 2012-08-08 Univ Tokyo CANCER TREATMENT DIAGNOSIS WITH ANTI-TM4SF20 ANTIBODY
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
KR20140059168A (ko) 2011-04-21 2014-05-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 시신경 척수염 치료용 조성물 및 치료 방법
CN102590531A (zh) * 2012-03-24 2012-07-18 广西壮族自治区肿瘤防治研究所 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法
MX2016004579A (es) * 2013-10-10 2016-12-09 Beth Israel Deaconess Medical Ct Inc Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
CN105793253B (zh) 2013-11-22 2019-08-23 法玛克亚公司 自分泌运动因子抑制剂化合物
MA47849A (fr) 2014-05-28 2020-01-29 Agenus Inc Anticorps anti-gitr et leurs procédés d'utilisation
AU2018323470A1 (en) * 2017-08-28 2020-03-19 Angiex, Inc. Anti-TM4SF1 antibodies and methods of using same

Also Published As

Publication number Publication date
EP3675906A4 (en) 2021-05-26
CN111565750A (zh) 2020-08-21
JP2020534351A (ja) 2020-11-26
CN111565750B (zh) 2023-11-03
AU2018323470A1 (en) 2020-03-19
JP2023071888A (ja) 2023-05-23
CA3074111A1 (en) 2019-03-07
US20200270360A1 (en) 2020-08-27
EP3675906A1 (en) 2020-07-08
US20220267461A1 (en) 2022-08-25
US20220153860A1 (en) 2022-05-19
WO2019046338A1 (en) 2019-03-07
US11208495B2 (en) 2021-12-28
JP7241080B2 (ja) 2023-03-16

Similar Documents

Publication Publication Date Title
MX2020002241A (es) Anticuerpos anti-tm4sf y métodos de uso de los mismos.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
SG10201901057UA (en) Anti-pd-l1 antibodies
MY186334A (en) Anti-her2 antibodies and immunoconjugates
TN2019000272A1 (en) Anti-ilt4 antibodies and antigen-binding fragments.
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
PH12016502518A1 (en) Monoclonal antibodies against her2 epitope and methods of use thereof
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
GEP20207166B (en) Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
SG10201900571YA (en) Anti-pd-1 antibodies
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
MX2022014695A (es) Anticuerpos anti-gitr y sus usos.
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2023006416A (es) Anticuerpos, usos y metodos.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
EA201692560A1 (ru) Моноклональные антитела против эпитопа her2 и способы их применения